Zalicus Inc. discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. We apply our selective ion-channel modulation platform and our combination high throughput screening capabilities to discover innovative therapeutics for both our internal product pipeline and our collaborators. Our drug discovery technology has identified Prednisporin, one of our most advanced clinical product candidates, on behalf of our partners at Fovea Pharmaceuticals (a division of Sanofi Aventis), and has also been seen as an important technology by our collaborators at Novartis and Amgen in support of their oncology research efforts.


Visit bctech for more information about Zalicus.